Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit (2016 - 2025)

China Pharma Holdings' Gross Profit history spans 16 years, with the latest figure at $150775.0 for Q4 2025.

  • For Q4 2025, Gross Profit rose 193.89% year-over-year to $150775.0; the TTM value through Dec 2025 reached -$131950.0, up 93.35%, while the annual FY2025 figure was -$131950.0, 93.35% up from the prior year.
  • Gross Profit reached $150775.0 in Q4 2025 per CPHI's latest filing, up from -$59654.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $301936.0 in Q4 2021 to a low of -$1.0 million in Q2 2024.
  • Average Gross Profit over 5 years is -$127166.4, with a median of -$136908.5 recorded in 2022.
  • Peak YoY movement for Gross Profit: tumbled 728.01% in 2021, then skyrocketed 204.99% in 2023.
  • A 5-year view of Gross Profit shows it stood at $301936.0 in 2021, then tumbled by 85.86% to $42682.0 in 2022, then crashed by 285.46% to -$79158.0 in 2023, then plummeted by 102.87% to -$160589.0 in 2024, then skyrocketed by 193.89% to $150775.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Gross Profit are $150775.0 (Q4 2025), -$59654.0 (Q3 2025), and -$87010.0 (Q2 2025).